The resurgence of covalent drugs
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Covalent drugs have proved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project. There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium. This review surveys the prevalence and pharmacological advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Covalent inhibitors, also known as irreversible inhibitors, are a class of inhibitors that bind to amino acid residues of target proteins through covalent bonds formed by mildly reactive functional groups to confer additional affinity, compared to that of non-covalent inhibitors, which achieve binding and inhibition of target proteins through non-covalent interactions such as hydrogen bond and van”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [30]
In the citing paper
“Recent improvements in structural biology and chemical reactivity have enabled the design and development of potent and selective covalent PPI inhibitors.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“Aided by recent advancements in structural biology and chemistry, covalent inhibitors have emerged as a potentially effective approach towards PPI inhibition [37, 38].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“In the 1970s, researchers reported that covalent drugs produce hepatotoxicity resulting from off-target effects via unselectively modifying non-target proteins with their highly reactive groups [37, 45].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“The initial binding step (K1) and the subsequent chemical reaction step (kinact) are two important factors determining the selectivity of covalent inhibitors (Fig. 7) [37].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“For example, approximately 50% of patients with non-small-cell lung carcinoma (NSCLC) who initially responded to reversible EGFR inhibitors relapsed owing to the emergence of tumour cells that express EGFR with mutations at T790M and/or L858R in the ATP binding sit”
BackgroundThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“An irreversible mechanism of action also helps to mitigate against competition by high intracellular concentrations of AT”
BackgroundLigand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Targeting proteases: successes, failures and future prospects
Turk, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2092 · Cited by 1,363
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Navigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 952
Cited by
Items 701–800 of 1,001
Gallina, A. M., Bork, P., & Bordo, D. (2014) · Journal of Molecular Recognition · doi:10.1002/jmr.2332 · Cited by 29
Storaska, A. J., Mei, J. P., Wu, M., Li, M., Wade, S. M., Blazer, L. L., Sjögren, B., Hopkins, C. R., Lindsley, C. W., Lin, Z., et al. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.09.007 · Cited by 29
Xu, J., Chen, A., Joy, J. K., Xavier, V. J., Ong, E. H., Hill, J., & Chai, C. L. L. (2013) · ChemMedChem · doi:10.1002/cmdc.201300231 · Cited by 30
Janero, D. R., Yaddanapudi, S., Zvonok, N., Subramanian, K. V., Shukla, V. G., Stahl, E. L., Zhou, L., Hurst, D. P., Wager‐Miller, J., Bohn, L., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00090 · Cited by 27
Price, K. E., Armstrong, C. M., Imlay, L. S., Hodge, D. M., Pidathala, C., Roberts, N. J., Park, J., Mikati, M. O., Sharma, R., Lawrenson, A. S., et al. (2016) · Scientific Reports · doi:10.1038/srep36777 · Cited by 36
Burgoyne, J. R., Prysyazhna, O. D., Richards, D. A., & Eaton, P. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09670 · Cited by 29
Singh, J., Evans, E., Hagel, M., Labinski, M., Dubrovskiy, A., Nacht, M., Petter, R. C., Prasad, A., Sheets, M., St Martin, T., et al. (2012) · MedChemComm · doi:10.1039/c2md20017a · Cited by 27
Self-citationLiang, X., Lv, F., Wang, B., Yu, K., Wu, H., Qi, Z., Jiang, Z., Chen, C., Wang, A., Miao, W., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01413 · Cited by 27
DNA-Compatible Solid-Phase Combinatorial Synthesis of β-Cyanoacrylamides and Related Electrophiles
Pels, K., Dickson, P., An, H., & Kodadek, T. J. (2018) · ACS Combinatorial Science · doi:10.1021/acscombsci.7b00169 · Cited by 27
Expanded toolbox for directing the biosynthesis of macrocyclic peptides in bacterial cells
Iannuzzelli, J. A., & Fasan, R. (2020) · Chemical Science · doi:10.1039/d0sc01699c · Cited by 27
Covalent inhibitors of GAPDH: From unspecific warheads to selective compounds
Galbiati, A., Zana, A., & Conti, P. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112740 · Cited by 29
Long, M. J. C., Rogg, C., & Aye, Y. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00537 · Cited by 26
Into the Fray! A Beginner's Guide to Medicinal Chemistry
Veale, C. G. L. (2021) · ChemMedChem · doi:10.1002/cmdc.202000929 · Cited by 29
Lloyd, M. D., Yevglevskis, M., Nathubhai, A., James, T. D., Threadgill, M. D., & Woodman, T. J. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00540a · Cited by 29
Rocha, J., Santos, A., Gama, H., Moser, P. C., Falcão, A. C., Pressman, P., Hayes, A. W., & Soares-da-Silva, P. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2290 · Cited by 32
Chu, H., Sethy, B., Hsieh, P., & Horng, J. (2021) · Viruses · doi:10.3390/v13091756 · Cited by 27
Kang, M. S., Khoo, Y. X. J., Jia, Z., & Loh, T. (2022) · Green Synthesis and Catalysis · doi:10.1016/j.gresc.2022.09.002 · Cited by 28
A Chemical Genetic Approach for Covalent Inhibition of Analogue-Sensitive Aurora Kinase
Koch, A., Rode, H. B., Richters, A., Rauh, D., & Hauf, S. (2012) · ACS Chemical Biology · doi:10.1021/cb200465c · Cited by 27
Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome
Totaro, K. A., Barthelme, D., Simpson, P. T., Jiang, X., Lin, G., Nathan, C., Sauer, R. T., & Sello, J. K. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00172 · Cited by 27
Pakavathkumar, P., Noël, A., Lecrux, C., Tubeleviciute-Aydin, A., Hamel, É., Ahlfors, J.-E. W., & LeBlanc, A. C. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0166-z · Cited by 31
Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective
Johnstone, S., & Albert, J. S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.03.084 · Cited by 28
Balakirski, G., & Merk, H. F. (2017) · Cutaneous and Ocular Toxicology · doi:10.1080/15569527.2017.1319379 · Cited by 27
Chemical Tools for Studying Lipid-Binding Class A G Protein–Coupled Receptors
Cooper, A. G., Singh, S., Hook, S. M., Tyndall, J. D. A., & Vernall, A. J. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.013243 · Cited by 31
Bedini, A., Fraternale, A., Crinelli, R., Mari, M., Bartolucci, S., Chiarantini, L., & Spadoni, G. (2018) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00216 · Cited by 29
Klein, P., Johé, P., Wagner, A., Jung, S., Kühlborn, J., Barthels, F., Tenzer, S., Distler, U., Waigel, W., Engels, B., et al. (2020) · Molecules · doi:10.3390/molecules25061451 · Cited by 27
Two-Step Covalent Docking with Attracting Cavities
Goullieux, M., Zoete, V., & Röhrig, U. F. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01055 · Cited by 28
“4,13,14 For example, irreversible covalent inhibitors of the epidermal growth factor receptor can circumvent acquired resistance to gefitinib.”
Innovative design and potential applications of covalent strategy in drug discovery
Tang, T., Luo, J., Zhang, D., Lü, Y., Liao, W., & Zhang, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117202 · Cited by 27
Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma
Mehdizadeh, A., Somi, M. H., Darabi, M., & Jabbarpour-Bonyadi, M. (2016) · Molecular Biology Reports · doi:10.1007/s11033-016-3943-9 · Cited by 26
Subcellular Redox Targeting: Bridging in Vitro and in Vivo Chemical Biology
Long, M. J. C., Poganik, J. R., Ghosh, S., & Aye, Y. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01148 · Cited by 32
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling
Macegoniuk, K., Kowalczyk, R., Rudzińska, A., Psurski, M., Wietrzyk, J., & Berlicki, Ł. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.02.022 · Cited by 27
Doornbos, M. L. J., Wang, X., Vermond, S. C., Peeters, L., Pérez‐Benito, L., Trabanco, A. A., Lavreysen, H., Cid, J. M., Heitman, L. H., Tresadern, G., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00051 · Cited by 28
“39 This is especially the case for neuroscience indications that often require chronic treatment, thus exacerbating such fears.”
The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents
Coll-Martínez, B., Delgado, A., & Crosas, B. (2020) · Molecules · doi:10.3390/molecules25245956 · Cited by 28
Serrano-Sterling, C., Becerra, D., Portilla, J., Rojas, H. A., Macias, M. A., & Castillo, J. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130944 · Cited by 26
Zanon, P. R. A., Lewald, L., & Hacker, S. M. (2019) · Angewandte Chemie · doi:10.1002/ange.201912075 · Cited by 29
Irreversible Inhibition of DNA Polymerase β by Small-Molecule Mimics of a DNA Lesion
Arian, D., Hedayati, M. A., Zhou, H., Bilis, Z., Chen, K., DeWeese, T. L., & Greenberg, M. M. (2014) · Journal of the American Chemical Society · doi:10.1021/ja411733s · Cited by 26
Wang, Y., Li, L., Zhang, B., Xing, J., Chen, S., Wan, W., Song, Y., Jiang, H., Jiang, H., Luo, C., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01785 · Cited by 26
Synthesis and antileukemic activities of C1–C10-modified parthenolide analogues
Kempema, A., Widen, J. C., Hexum, J. K., Andrews, T. E., Wang, D., Rathe, S. K., Meece, F. A., Noble-Orcutt, K. E., Sachs, Z., Largaespada, D. A., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.05.037 · Cited by 26
Marella, A., Akhter, M., Shaquiquzzaman, M., Tanwar, O., Verma, G., & Alam, M. M. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1188-5 · Cited by 26
Stura, E. A., Roux, L. L., Guitot, K., Garcia, S., Bregant, S., Beau, F., Vera, L., Collet, G., Ptchelkine, D., Bakirci, H., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.396697 · Cited by 30
Lebraud, H., Coxon, C. R., Archard, V. S., Bawn, C., Carbain, B., Matheson, C. J., Turner, D. M., Cano, C., Griffin, R. J., Hardcastle, I. R., et al. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob41806e · Cited by 26
Shawky, A. M., Almalki, F. A., Alzahrani, H. A., Abdalla, A. N., Youssif, B. G. M., Ibrahim, N. A., Gamal, M., El-Sherief, H. A. M., Abdel‐Fattah, M. M., Hefny, A. A., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116704 · Cited by 27
Costacurta, F., Dodaro, A., Bante, D., Schöppe, H., Peng, J.-Y., Sprenger, B., He, X. C., Moghadasi, S. A., Egger, L. M., Fleischmann, J., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012522 · Cited by 28
“Then, cDNA was synthesized from isolated viral RNA by RevertAid RT Reverse Transcription Kit (Thermo Fisher Scientific).”
MethodBoronic Acids as Probes for Investigation of Allosteric Modulation of the Chemokine Receptor CXCR3
Bernat, V., Admas, T. H., Brox, R., Heinemann, F. W., & Tschammer, N. (2014) · ACS Chemical Biology · doi:10.1021/cb500678c · Cited by 25
Clement, L. L., Tsakos, M., Schaffert, E. S., Scavenius, C., Enghild, J. J., & Poulsen, T. B. (2015) · Chemical Communications · doi:10.1039/c5cc04500b · Cited by 25
Kawamura, S., Unno, Y., Tanaka, M., Sasaki, T., Yamano, A., Hirokawa, T., Kameda, T., Asai, A., Arisawa, M., & Shuto, S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400542h · Cited by 25
Sarwono, A. E. Y., Mitsuhashi, S., Kabir, M. H. B., Shigetomi, K., Okada, T., Ohsaka, F., Otsuguro, S., Maenaka, K., Igarashi, M., Kato, K., et al. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1540474 · Cited by 25
Huang, Y., Wei, L., Han, X., Chen, H., Ren, Y., Xu, Y., Song, R., Rao, L., Chen, S., Peng, C., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111749 · Cited by 24
Robinson, R. M., Reyes, L., Duncan, R. M., Bian, H., Strobel, E. D., Hyman, S. L., Reitz, A. B., & Dolloff, N. G. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111906 · Cited by 27
A Covalent Calmodulin Inhibitor as a Tool to Study Cellular Mechanisms of K-Ras-Driven Stemness
Okutachi, S., Manoharan, G. B., Kiriazis, A., Laurini, C., Catillon, M., McCormick, F. P., Yli‐Kauhaluoma, J. T., & Abankwa, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.665673 · Cited by 23
Combined Biophysical Chemistry Reveals a New Covalent Inhibitor with a Low-Reactivity Alkyl Halide
Li, T., Maltais, R., Poirier, D., & Lin, S. (2018) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.8b02225 · Cited by 28
Du, H., Jiang, D., Gao, J., Zhang, X., Jiang, L., Zeng, Y., Wu, Z., Shen, C., Xu, L., Cao, D., et al. (2022) · Research · doi:10.34133/2022/9873564 · Cited by 28
High-Throughput Screening for Growth Inhibitors Using a Yeast Model of Familial Paraganglioma
Bancos, I., Bida, J. P., Tian, D., Bundrick, M., John, K., Holte, M. N., Her, Y. F., Evans, D. L., Saenz, D. T., Poeschla, E. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056827 · Cited by 27
Kazi, A., Özcan, S., Tecleab, A., Sun, Y., Lawrence, H. R., & Sebti, S. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.533950 · Cited by 25
Synthesis of piperlogs and analysis of their effects on cells
Bošković, Ž., Hussain, M. M., Adams, D., Dai, M., & Schreiber, S. L. (2013) · Tetrahedron · doi:10.1016/j.tet.2013.05.080 · Cited by 28
Mariaule, G., Cesco, S. D., Airaghi, F., Kurian, J., Schiavini, P., Rocheleau, S., Huskić, I., Auclair, K., Mittermaier, A., & Moitessier, N. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01296 · Cited by 27
Häußler, D., Mangold, M., Furtmann, N., Braune, A., Blaut, M., Bajorath, J., Stirnberg, M., & Gütschow, M. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201600206 · Cited by 27
Schulz, R., Atef, A., Becker, D., Gottschalk, F., Tauber, C., Wagner, S., Arkona, C., ABDEL‐HAFEZ, A. A., Farag, H. H. A., Rademann, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01440 · Cited by 25
Widen, J. C., Kempema, A., Baur, J. W., Skopec, H. M., Edwards, J. T., Brown, T. J., Brown, D. A., Meece, F. A., & Harki, D. A. (2018) · ChemMedChem · doi:10.1002/cmdc.201700752 · Cited by 25
The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer
Cerrato, A., Visconti, R., & Celetti, A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0799-8 · Cited by 24
“Anyway, the majority of small molecules inhibit multiple kinases because the ATP-binding sites are highly conserved, leading to ‘off-target’ effects [13].”
BackgroundRan, F., Liu, Y., Liu, M., Zhang, D., Wang, P., Dong, J., Tang, W., & Zhao, G. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102943 · Cited by 25
“Irreversible BTK inhibitors keep warheads such as the acrylamide group and chloroacetamide group in the structures which can form a covalent bond by Michael addition, nucleophilic addition, addition-elimination or nucleophilic substitution reactions with the conserved noncatalytic cysteine residue (Cys481) of BTK to a…”
BackgroundCevher, H. A., Schaller, D., Gandini, M. A., Kaplan, O., Gambeta, E., Zhang, F. X., Çelebi̇er, M., Tahir, M. N., Zamponi, G. W., Wolber, G., et al. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103187 · Cited by 25
“Despite generally being avoided during the drug design process, drugs that covalently modify their target have been approved as treatments for diverse clinical indications ranging from obesity to cancer [13].”
BackgroundLi, Q., Wang, Z., Zheng, Q., & Liu, S. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.08.016 · Cited by 24
“Historically, the drug discovery practice mainly focuses on noncovalent drugs due to potential off-target effects and toxicity issues of irreversible covalent drugs [13].”
Advancements in Assay Technologies and Strategies to Enable Drug Discovery
Busby, S. A., Carbonneau, S., Concannon, J. B., Dumelin, C. E., Lee, Y., Numao, S., Renaud, N., Smith, T. M., & Auld, D. S. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00495 · Cited by 29
On the Mechanism of Dimethylarginine Dimethylaminohydrolase Inactivation by 4-Halopyridines
Johnson, C. M., Monzingo, A. F., Ke, Z., Yoon, D.-W., Linsky, T. W., Guo, H., Robertus, J. D., & Fast, W. L. (2011) · Journal of the American Chemical Society · doi:10.1021/ja2033684 · Cited by 25
ALARM NMR for HTS Triage and Chemical Probe Validation
Dahlin, J. L., Cuellar, M., Singh, G., Nelson, K. M., Strasser, J. M., Rappe, T., Xia, Y., Veglia, G., & Walters, M. A. (2018) · Current Protocols in Chemical Biology · doi:10.1002/cpch.35 · Cited by 25
Protein Haptenation and Its Role in Allergy
Aleksić, M., & Meng, X. (2024) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.4c00062 · Cited by 26
Discovery of Thioether-Cyclized Macrocyclic Covalent Inhibitors by mRNA Display
Lan, T., Peng, C., Yao, X., Chan, R. S. T., Wei, T., Rupanya, A., Radakovic, A., Wang, S., Chen, S., Lovell, S., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c07851 · Cited by 24
The Die Is Cast: Precision Electrophilic Modifications Contribute to Cellular Decision Making
Long, M. J. C., & Aye, Y. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00261 · Cited by 24
Miao, L., & Tian, H. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1648477 · Cited by 24
“With the development of principles of rational molecular design and targeted covalent inhibitors (TCI) constantly being developed clinically, covalent ERK1/2 inhibitors should see a resurgence of research interest in the coming years [92].”
BackgroundPulz, R., Angst, D., Dawson, J., Gessier, F., Gutmann, S., Hersperger, R., Hinniger, A., Janser, P., Koch, G., Révész, L., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00317 · Cited by 25
Chen, F.-Y., Li, X., Zhan, G., Liu, H., Kang, B., Zhang, S.-C., Peng, C. Y., & Han, B. (2020) · Tetrahedron Letters · doi:10.1016/j.tetlet.2020.151806 · Cited by 24
Electrophilic Natural Products as Drug Discovery Tools
Gehrtz, P., & London, N. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.03.008 · Cited by 25
Reversible covalent inhibitors suppress enterovirus 71 infection by targeting the 3C protease
Liu, M., Xu, B., Ma, Y., Shang, L., Ye, S., & Wang, Y. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105102 · Cited by 24
Zhang, Z., Wang, Y., Chen, X., Song, X., Tu, Z., Chen, Y., Zhang, Z., & Ding, K. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116457 · Cited by 24
Exploration of BAY 11-7082 as a Potential Antibiotic
Coles, V. E., Darveau, P., Zhang, X., Harvey, H., Henriksbo, B. D., Yang, A., Schertzer, J. D., Magolan, J., & Burrows, L. L. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00522 · Cited by 25
Covalent inhibitors of EZH2: Design, synthesis and evaluation
Zhang, Q., Chen, X., Hu, X., Duan, X., Wan, G., Li, L., Feng, Q., Zhang, Y., Wang, N., & Yu, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112617 · Cited by 27
Covalent Protein Modification: An Unignorable Factor for Bisphenol A-Induced Hepatotoxicity
Hu, X., Wu, J., Wen, M., Long, F., Pan, H., Peng, T., Yao, X., & Li, N. (2022) · Environmental Science & Technology · doi:10.1021/acs.est.2c01307 · Cited by 26
Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics
Pavan, M., & Moro, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054401 · Cited by 26
“…inhibitors are usually associated with selectivity problems, due to their ability to react promiscuously with a plethora of nucleophile moieties [183]; second, the peptidomimetic scaffold is usually associated with suboptimal pharmacokinetic properties that affect the preferred route of…”
BackgroundGuo, Y., Wang, N., Zhong, Y., Li, W., Li, Y., Wang, G., Yao, Y., Shi, Y., Chen, L., Wang, X., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11150 · Cited by 24
Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease
Ngo, C., Fried, W., Aliyari, S. R., Feng, J. J., Qin, C., Zhang, S., Yang, H., Shanaa, J., Feng, P., Cheng, G., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00810 · Cited by 23
Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy
Kirschner, T., Müller, M. P., & Rauh, D. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02403 · Cited by 24
Appendino, G., Minassi, A., Collado, J. A., Pollastro, F., Chianese, G., Taglialatela‐Scafati, O., Ayyari, M., Garcia, V., & Muñóz, E. (2015) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201500237 · Cited by 24
Silpa, L., Niepceron, A., Laurent, F., Brossier, F., Pénichon, M., Enguehard‐Gueiffier, C., Abarbri, M., Silvestre, A., & Pétrignet, J. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.11.018 · Cited by 24
Dasari, R., Carvalho, A., Medellin, D. C., Middleton, K. N., Hague, F., Volmar, M. N. M., Frolova, L. V., Rossato, M. F., Chapa, J. J. D. L., Dybdal‐Hargreaves, N. F., et al. (2015) · ChemMedChem · doi:10.1002/cmdc.201500360 · Cited by 24
Fan, P. W., Zhang, D., Halladay, J. S., Driscoll, J. P., & Khojasteh, S. C. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.070169 · Cited by 26
Targeting duplex DNA with the reversible reactivity of quinone methides
Huang, C., Liu, Y., & Rokita, S. E. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.9 · Cited by 25
Biophysics: for HTS hit validation, chemical lead optimization, and beyond
Genick, C. C., & Wright, S. K. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1349096 · Cited by 24
Enzymatic formation of curcumin in vitro and in vivo
Wang, J., Xiong, T., Zhou, J., He, H., Wu, D., Du, X., Li, X., & Xu, B. (2018) · Nano Research · doi:10.1007/s12274-018-1994-z · Cited by 24
Drug–protein adducts: past, present, and future
Baillie, T. A. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02567-8 · Cited by 25
Self-citationCovalent flexible peptide docking in Rosetta
Tivon, B., Gabizon, R., Somsen, B. A., Cossar, P. J., Ottmann, C., & London, N. (2021) · Chemical Science · doi:10.1039/d1sc02322e · Cited by 26
Irreversible Enzyme Inactivators
Copeland, R. A. (2013) · Wiley eBooks · doi:10.1002/9781118540398.ch9 · Cited by 23
Reinecke, M., Heinzlmeir, S., Wilhelm, M., Médard, G., Klaeger, S., & Küster, B. (2019) · Methods and principles in medicinal chemistry · doi:10.1002/9783527818242.ch4 · Cited by 29
Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans
Meng, J., Zhang, H., Bao, J.-J., Chen, Z.-D., Liu, X.-Y., Zhang, Y.-F., Jiang, Y., Miao, L.-Y., & Zhong, D.-F. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00667-8 · Cited by 23
“EGFR-TKIs were designed to combine a nuclear structure with electrophilic groups, the former of which could competitively bind with the target and the latter of which covalently binds with a cysteine residue of the target [11].”
BackgroundWen, W., Cao, H., Huang, Y., Tu, J., Chen, W., Wan, J., Han, X., Chen, H., Liu, J., Rao, L., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02102 · Cited by 22
Advances in reversible covalent kinase inhibitors
Zhao, Z., & Bourne, P. E. (2024) · Medicinal Research Reviews · doi:10.1002/med.22084 · Cited by 29
“Further modification of the scaffolds, such as pyridinyl substitution (21-23), did not impact the potency (IC50) or residence time (t) (Figure 4f).”
BackgroundTargeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer
Sharp, A., Welti, J. C., Blagg, J., & Bono, J. S. D. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1137 · Cited by 23
STAT3 Inhibitors in Cancer: A Comprehensive Update
Bharadwaj, U., Kasembeli, M. M., & Tweardy, D. J. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-42949-6_5 · Cited by 26
Synthesis of Diverse N-Acryloyl Azetidines and Evaluation of Their Enhanced Thiol Reactivities
Palkowitz, M. D., Tan, B., Hu, H., Roth, K. D. W., & Bauer, R. A. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b00788 · Cited by 23
Discovery of Targeted Covalent Natural Products against PLK1 by Herb-Based Screening
Liang, H., Liu, H., Kuang, Y., Chen, L., Ye, M., & Lai, L. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00074 · Cited by 23
Protocol for Stereoselective Construction of Highly Functionalized Dienyl Sulfonyl Fluoride Warheads
Zhang, Z.-W., Wang, S., Fang, W., Lekkala, R., & Qin, H. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c01877 · Cited by 23
Metadata
- Authors
- Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A.
- Affiliations
- University of Washington (US)
- Boston University (US)
- Corresponding author
- Singh, Juswinder
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04
- Volume
- 10
- Issue
- 4
- Pages
- 307-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2010993054
- Cited by
- 1,873
- References
- 71
- Citations by year
- 2026: 136 · 2025: 150 · 2024: 148 · 2023: 137 · 2022: 145 · 2021: 162 · 2020: 152 · 2019: 98 · 2018: 132 · 2017: 125 · 2016: 141 · 2015: 96 · 2014: 81 · 2013: 85 · 2012: 66
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM094551)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- covalent inhibitors, drug safety, covalent drug design, targeted covalent inhibitors
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Structure-Activity Relationship, Drug Design, Drug Delivery Systems, Drug Discovery, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.